IBI3002 Safety Study in Healthy and Asthmatic Participants Underway
A randomized, double-blind, placebo-controlled study is evaluating the safety and tolerability of IBI3002 in healthy participants and asthma patients.
Asset / Drug
Drug and asset intelligence for IBI3002 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.